GLPwatch
Exenatide Once Weekly for Smoking Cessation
NCT02975297 · Completed
Last updated 2026-05-28This clinical trial tested whether a weekly injection of exenatide could help adults who smoke quit smoking.
Status Completed The study has finished.
Phase Phase1, Phase2
Type Interventional (clinical trial)
Design Randomized, triple-blind treatment study
Participants 84 people
Who can join Ages 18–75 · all sexes
Timeline Started 2016-07 · est. completion 2020-01
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02975297 ↗
Description as written by the study sponsor.
The purpose of this study is to identify a potential new treatment for smoking cessation.
Treatments tested
- Exenatide also known as Bydureon Drug
Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
- NRT also known as Nicotine patch Drug
Nicotine Patch (21mg) / 24 hours.
- Counseling also known as Smoking cessation counseling Behavioral
Brief individual behavioral smoking cessation counseling.
- Placebo Drug
Normal saline.
| Main thing measured | Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Conditions studied | Smoking Cessation |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02975297 ↗